.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Harvard Business School
Federal Trade Commission
Merck
McKinsey
Argus Health
Farmers Insurance
Fuji
Cipla
Medtronic

Generated: December 13, 2017

DrugPatentWatch Database Preview

Mipomersen sodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for mipomersen sodium and what is the scope of mipomersen sodium freedom to operate?

Mipomersen sodium
is the generic ingredient in one branded drug marketed by Kastle Theraps Llc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mipomersen sodium has five hundred and seventy-seven patent family members in twenty-six countries.

Two suppliers are listed for this compound.

Summary for mipomersen sodium

US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Clinical Trials: 2,431
Drug Prices:see low prices
DailyMed Link:mipomersen sodium at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: mipomersen sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013► Subscribe► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013► Subscribe► Subscribe
Kastle Theraps LlcKYNAMROmipomersen sodiumSOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: mipomersen sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,735,364Antisense modulation of apolipoprotein B expression► Subscribe
5,760,202 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
RE44760Antisense modulation of apolipoprotein B-expression► Subscribe
7,888,324Antisense modulation of apolipoprotein B expression► Subscribe
6,642,367 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
7,803,930Antisense modulation of apolipoprotein B-expression► Subscribe
6,222,025 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
5,861,493 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: mipomersen sodium

Country Document Number Estimated Expiration
European Patent Office0544792► Subscribe
Canada2246229► Subscribe
European Patent Office0817787► Subscribe
Germany69127903► Subscribe
Australia757894► Subscribe
Australia6252896► Subscribe
Austria219095► Subscribe
Japan2010193894► Subscribe
European Patent Office0975654► Subscribe
European Patent Office1080225► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Citi
Chinese Patent Office
Boehringer Ingelheim
Healthtrust
US Department of Justice
Federal Trade Commission
McKinsey
Teva
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot